Jb Chemicals & Pharmaceuticals Ltd. · NSE:JBCHEPHARM
Jb Chemicals & Pharmaceuticals — Q1 FY24 Earnings Presentation
24 slides from Jb Chemicals & Pharmaceuticals's earnings presentation, Aug 9, 2023
Slide 1: Company presentation cover letter to NSE
August 9, 2023 National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400051. Stock Symbol: JBCHEPHARM Dear Sir, Sub: Company Presentation Enclosed is Company’s presentation on financial results for the quarter ended on J
Slide 2: JB Pharma – Q1 FY24 Investor Presentation
JB Pharma – Q1 FY24 Investor Presentation August 9, 2023 www.jbpharma.com jbpharma/
Slide 3: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 4: JB Pharma – Looking ahead
>. Synergistic acquisitions productivity Domestic outperformer Jp) “ E Gl leader Consistency of delivery _ Strong FCF forG000 HEALTH o — Dosage i i op Global regulatory approvals Medicated/Herbal lozenges a . 3 Leadership Key therapies Pillar Brands e she B PHARMA °s Dosage forms State of the art fa
Slide 5: Company key facts
46 6 40+ Top 5 Brands among top 300 brands Global manufacturer of Years of operations with Regulated/semi-regulated (IQVIA MAT Mar’23 data), medicated/herbal lozenges consistent track record markets of presence through contributing over 60% of representing a substantial across multiple businesses di
Slide 6: Corporate Snapshot – Financial Overview
Corporate Snapshot – Financial Overview Revenue (INR cr) PAT (INR cr) ^Op EBITDA Margin (%) ROE (%) ROCE (%) 27.4% 42% 25.0% 24.3% 21.3% 18.6% 3,149 29% 15.4% 24% # 2,424 22% 21% 2,043 25% 1,643 1,775 15% 1,413 19% 18% 17% 449 410 13% 272 386 139 194 10% FY18 FY19 FY20 FY21 FY22 FY23 FY18 FY19 FY20
Slide 7: World Class Manufacturing Facilities
World Class Manufacturing Facilities 8 40+ 10 State of the Art Global Dosage forms manufacturing Regulatory produced facilities Accreditations Tablets Capsules Liquids IV Infusions Ampules Vials Ointments Cold Rubs Lozenges Sips 6
Slide 8: Q1 FY24 Business Performance
Q1 FY24 Business Performance
Slide 9: CEO’s Message
CEO’s Message “JB Pharma delivered a good quarter driven by focused execution. Our domestic business continued its growth trajectory through strong momentum in our chronic portfolio and acquired assets. Our big brands, especially in chronic segment, continue to outpace the market and have reached ne
Slide 10: Results Overview: Q1 FY24 vs Q1 FY23
Results Overview: Q1 FY24 vs Q1 FY23 Revenues (INR crores) 30% 3,149 2,424 14% o JB Pharma recorded growth of 14% clocking revenue of INR 896 crores 785 896 o Domestic formulations business stood at INR 489 crores recording growth of 17% Q1 FY23 Q1 FY24 FY22 FY23 • The acquired brands continue to de
Slide 11: EBITDA Analysis
EBITDA Analysis INR crore Q1 FY24 Q1 FY23 FY23 FY22 Revenue 896 785 3149 2424 Reported EBITDA 232 173 696 543 Non Cash ESOP Charge 11 17 69 62 Included in Employee Benefits expense Operating EBITDA (excluding ESOP charge) 243 190 765 605 Operating EBITDA margins 27.1% 24.2% 24.3% 24.9% 10
Slide 12: Financial Overview Q1 FY24 vs Q1 FY23
Financial Overview Q1 FY24 vs Q1 FY23 Op. EBITDA* (INR crores) 24.3% 24.9% 765 o Operating EBITDA* increased by 28% to INR 243 crores • Operating EBITDA* margin for the quarter was 605 27.1%, an improvement of 290 bps 27.1% o Gross Margins for the quarter was 65.4% vs 62.7%, an 24.2% 26% improvement
Slide 13: Domestic Business Q1 FY24 vs Q1 FY23
Domestic Business Q1 FY24 vs Q1 FY23 Domestic Formulations (INR crores) o Domestic business revenue for the quarter was INR 489 17% crores, recording growth of 17% o JB Pharma continues to be the fastest growing company 489 amongst the Top 25 in the IPM (IQVIA MAT Jun’23 data) o Sales for the acute
Slide 14: JB continues as one of the fastest growing companies
JB continues as one of the fastest growing companies, maintaining a market beating performance Among top 25, JB is the fastest Leadership position growing pharma company in in the covered markets the IPM Fastest growing company among the Top 25 in the IPM as per IQVIA MAT Jun’23 data 21% Vs IPM grow
Slide 15: JB continues to dominate its CVM while strengthening Chronic portfolio
JB continues to dominate its CVM while also strengthening its Chronic portfolio JB Pharma Outperforming its CVM JB Pharma Strengthening its Chronic footprint 26.7% 20.7% 22.8% 13.6% 12.6% 10.8% 12.1% 9.9% MAT June'23 vs MAT Jun'22 Q1 FY24 vs Q1 FY23 MAT June'23 vs MAT Jun'22 Q1 FY24 vs Q1 FY23 CVM J
Slide 16: JB’s Prescriptions growing at a market beating pace
JB’s Prescriptions growing at a market beating pace JB Pharma Total Prescriptions (in Lakhs) JB Pharma Total Prescriptions per Doctor (P/D) 12% 1542 46 1379 43 MAT June'22 MAT June'23 MAT June'22 MAT June'23 JB Pharma Total Prescribers (in ‘000) Total prescriptions for JB grew at 12% as per MAT 5% J
Slide 17: Brands Getting Bigger: Sales and Ranks continue to Improve
Brands Getting Bigger: Sales and Ranks continue to Improve MAT June’22 MAT June’23 Value Sales* Value Sales* MAT June’22 Rank MAT June’23 Rank RANTAC 301 357 #41 #35 CILACAR 280 343 #49 #40 METROGYL 163 196 #165 #145 NICARDIA 117 156 #220 #162 CILACAR-T 114 146 #190 #178 AZMARDA 81 115 #354 #270 16
Slide 18: Acquisitions gaining significant momentum
Acquisitions gaining significant momentum Month of IQVIA MAT Jun’23 Acquisition Sales Probiotics Portfolio INR 163 cr INR 208 cr IQVIA MAT Jan’22 Sales Feb’22 Sporlac INR 63 cr INR 94 cr IQVIA MAT Jan’22 Sales Azmarda Apr’22 INR 78 cr INR 115 cr IQVIA MAT Mar’22 Sales 17
Slide 19: Recently acquired ‘Razel’ portfolio gaining traction
Recently acquired ‘Razel’ portfolio gaining traction 6.6 6.7 5.9 5.5 Average monthly sales in CY 22 before acquisition was INR 5.5 crores Razel monthly sales recorded was INR 5.9 cr (Apr’23) INR 6.6 cr (May’23) & INR 6.7 cr (Jun’23) Brand extensions performing ahead of expectations, all registering
Slide 20: International Business Q1 FY24 vs Q1 FY23
International Business Q1 FY24 vs Q1 FY23 11% o International Business recorded 11% growth to INR 407 407 12% crores 366 o International Formulations business registered growth of 275 12% to INR 275 crores 245 • South Africa business declined YoY as we continue to 19% focus on the private market and
Slide 21: Q1 FY24 Financial Performance (Consolidated)
Q1 FY24 Financial Performance (Consolidated) Particulars Q1 FY24 Q1 FY23 Growth% FY 23 FY22 Growth% Revenue from Operations 896 785 14% 3149 2424 30% Cost of Goods Sold 310 293 6% 1168 843 39% Gross Profit 586 492 19% 1981 1581 25% Gross Profit Margins 65.4% 62.7% 62.9% 65.2% Employee Benefit Expens
Slide 22: JB Pharma – Looking ahead
JB Pharma – Looking ahead Growth objectives supported by lean organization structure and strong governance framework Domestic business to consistently outperform Continued growth momentum in International market growth driven by business Big brands becoming bigger Strong delivery in CDMO busines
Slide 23: About JB Pharma
About JB Pharma J.B. Pharma (BSE: 506943 | NSE: JBCHEPHARM | ISIN: For further information, please INE572A01028), established in 1976, is one of the fastest growing pharmaceutical companies in India and a contact: leading player in the hypertension segment. Besides its strong India presence, which a
Slide 24: Thank you
GOOD PEOPLE _for GOOD HEALTH Thank you 000 www.jbpharma.com
J. B. Chemicals & Pharmaceuticals — Q1 FY24 Earnings Presentation on 6ix